GlassScriptPhysician profile
Kevin A Lisman
NPI 1467451971
$13,444.88
in general payments reported to CMS, 2019-2025
49 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,705 · 2020: $1,550 · 2021: $2,999 · 2022: $2,332 · 2023: $1,447 · 2024: $1,939 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,194.43 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Merlin@Home |
| Pfizer INC. | $1,091.68 | 2019-2025 | |
| Biotronik INC. | $1,031.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,013.87 | 2020-2025 | Eliquis, Camzyos |
| Amgen INC. | $866.87 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $809.58 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $605.20 | 2020-2022 | |
| Boston Scientific Corporation | $537.42 | 2019-2025 | Watchman Flx, Accolade Sr, General - Therapies |
| Merck Sharp & Dohme LLC | $444.00 | 2022-2025 | Verquvo, Capvaxive |
| Bolton Medical INC | $355.08 | 2021-2022 | |
| Esperion Therapeutics, INC. | $340.07 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $257.12 | 2019-2023 | Lexiscan |
| Angiodynamics, INC. | $244.46 | 2022-2025 | Auryon Laser System 100-120 Vac |
| Sanofi-Aventis U.S. LLC | $219.69 | 2019-2024 | |
| Medtronic Vascular, INC. | $192.27 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.